Sutro Biopharma Inc (FRA:S09)
€ 4 0.26 (6.95%) Market Cap: 336.60 Mil Enterprise Value: -36.24 Mil PE Ratio: 0 PB Ratio: 2.37 GF Score: 66/100

Sutro Biopharma Inc at Wells Fargo Healthcare Conference Transcript

Sep 09, 2022 / 02:25PM GMT
Release Date Price: €5.7 (+2.70%)
James John Shin
Wells Fargo Securities, LLC, Research Division - Associate Equity Analyst

Good morning, everyone. Thanks for being here. My name is James Shin. I'm one of the biotech analyst at Wells Fargo. Today, I'm joined up here with the CEO of Sutro Biopharma. Bill, thank you for being here.

William J. Newell
Sutro Biopharma, Inc. - CEO & Director

Thanks, James. It's a pleasure to be here.

James John Shin
Wells Fargo Securities, LLC, Research Division - Associate Equity Analyst

Thank you so much. For those that aren't familiar with Sutro, do you mind giving us a quick overview?

William J. Newell
Sutro Biopharma, Inc. - CEO & Director

Yes. Sutro is a very unique company in the way in which we make what we believe are best-in-class cancer therapeutics. Most people make cancer therapeutics using antibodies that are derived from how [CHO] cells. We have a cell-free protein synthesis technology that is unique and differentiated. And I can explain some of the

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot